Neurodegenerative diseases, typically characterized by a progressive nervous system dysfunction, represent a heavy burden both in terms of patient suffering and economic cost. The prevalence of ...

SEAMARK: Randomized phase 2 study of pembrolizumab + encorafenib + cetuximab versus pembrolizumab alone for first-line treatment of BRAF V600E-mutant and microsatellite instability-high ...

Danish start-up Fuse Vectors has received $5.2 million in preseed financing to further develop their gene therapy technology. The company has developed a cell-free platform for producing ...